



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1645 #13  
3/6/02

Attorney Docket No.: DEX-0117

Inventors: Salceda et al.

Serial No.: 09/721,183

Filing Date: November 22, 2000

Examiner: Davis, N.

Group Art Unit: 1645

Title: A Novel Method of Diagnosing,  
Monitoring, Staging, Imaging and  
Treating Breast Cancers

RECEIVED

MAR 06 2002

TECH CENTER 1600/2900

I, Nathan P. Letts, Registration No. 36,581, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents and Trademarks, Washington, D.C. 20231.

On this date, February 20, 2002

Nathan P. Letts, Registration No. 36,581

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

( ) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the

RECEIVED  
MAR 06 2002  
TECH CENTER 1600/2900

date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

(XX) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is set forth below; or

(XX) The fee of \$180.00 as set forth in §1.17(p) is attached.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

(XX) A copy of the of the PCT Search Report for PCT application PCT/US00/32056 which corresponds to the subject US application 09/721,183 is included.

( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449

(modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. \_\_\_\_\_, filed , for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

TECHNICAL CENTER  
MAR 06 2002  
RECEIVED


(XX) Due to the large size of some references, only relevant portions have been submitted. The included portions are as follows: WO 01/51628 A2 (pages 1-105, Table 1 pg. 368, Table 2 pg. 438, Table 3 pg. 524, Table 4 pg. 501, Table 5, Table 6). Full text of abbreviated reference is available if requested.

( ) Reference @@ is in a foreign language. Therefore, a Geneseq Patent search report is attached to demonstrate relevance.

(XX) All listed references are in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-0434. This form is submitted in duplicate.

Respectfully submitted,



Nathan P. Letts  
Registration No. 36,581

Date: February 20, 2002

DiaDexus, Inc.  
343 Oyster Point Blvd.  
South San Francisco, CA 94080  
(650) 246-6400